TY - JOUR
T1 - Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the colon cancer family registry
AU - Holmes, Rebecca S.
AU - Zheng, Yingye
AU - Baron, John A.
AU - Li, Lin
AU - McKeown-Eyssen, Gail
AU - Newcomb, Polly A.
AU - Stern, Mariana C.
AU - Haile, Robert W.
AU - Grady, William M.
AU - Potter, John D.
AU - Le Marchand, Loic
AU - Campbell, Peter T.
AU - Figueiredo, Jane C.
AU - Limburg, Paul J.
AU - Jenkins, Mark A.
AU - Hopper, John L.
AU - Ulrich, Cornelia M.
PY - 2010/8
Y1 - 2010/8
N2 - Background: Supplement use among cancer patients is high, and folic acid intake in particular may adversely affect the progression of colorectal cancer. Few studies have evaluated the use of folic acid-containing supplements (FAS) and its predictors in colorectal cancer patients. Objective: To assess the use of FAS, change in use, and its predictors after colorectal cancer diagnosis. Design: We used logistic regression models to investigate predictors of FAS use and its initiation after colorectal cancer diagnosis in 1,092 patients recruited through the Colon Cancer Family Registry. Results: The prevalence of FAS use was 35.4% before and 55.1% after colorectal cancer diagnosis (P = 0.004). Women were more likely than men to use FAS after diagnosis [odds ratio (OR), 1.47; 95% confidence interval (95% CI), 1.14-1.89], as were those consuming more fruit (Ptrend < 0.0001) or vegetables (Ptrend = 0.001), and U.S. residents (P < 0.0001). Less likely to use FAS after diagnosis were nonwhite patients (OR, 0.66; 95% CI, 0.45-0.97), current smokers (OR, 0.67; 95% CI, 0.46-0.96), and those with higher meat intake (Ptrend = 0.03). Predictors of FAS initiation after diagnosis were generally similar to those of FAS use after diagnosis, although associations with race and vegetable intake were weaker and those with exercise stronger. Conclusions: Our analysis showed substantial increases in the use of FAS after diagnosis with colorectal cancer, with use or initiation more likely among women, Caucasians, U.S. residents, and those with a healthpromoting life-style. Impact: Studies of cancer prognosis that rely on prediagnostic exposure information may result in substantial misclassification.
AB - Background: Supplement use among cancer patients is high, and folic acid intake in particular may adversely affect the progression of colorectal cancer. Few studies have evaluated the use of folic acid-containing supplements (FAS) and its predictors in colorectal cancer patients. Objective: To assess the use of FAS, change in use, and its predictors after colorectal cancer diagnosis. Design: We used logistic regression models to investigate predictors of FAS use and its initiation after colorectal cancer diagnosis in 1,092 patients recruited through the Colon Cancer Family Registry. Results: The prevalence of FAS use was 35.4% before and 55.1% after colorectal cancer diagnosis (P = 0.004). Women were more likely than men to use FAS after diagnosis [odds ratio (OR), 1.47; 95% confidence interval (95% CI), 1.14-1.89], as were those consuming more fruit (Ptrend < 0.0001) or vegetables (Ptrend = 0.001), and U.S. residents (P < 0.0001). Less likely to use FAS after diagnosis were nonwhite patients (OR, 0.66; 95% CI, 0.45-0.97), current smokers (OR, 0.67; 95% CI, 0.46-0.96), and those with higher meat intake (Ptrend = 0.03). Predictors of FAS initiation after diagnosis were generally similar to those of FAS use after diagnosis, although associations with race and vegetable intake were weaker and those with exercise stronger. Conclusions: Our analysis showed substantial increases in the use of FAS after diagnosis with colorectal cancer, with use or initiation more likely among women, Caucasians, U.S. residents, and those with a healthpromoting life-style. Impact: Studies of cancer prognosis that rely on prediagnostic exposure information may result in substantial misclassification.
UR - http://www.scopus.com/inward/record.url?scp=77955462686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955462686&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-09-1097
DO - 10.1158/1055-9965.EPI-09-1097
M3 - Article
C2 - 20696661
AN - SCOPUS:77955462686
SN - 1055-9965
VL - 19
SP - 2023
EP - 2034
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 8
ER -